Advertisement

Related Videos

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

David A. Hyman, MD, JD, on Inclusive Shared Savings

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Advertisement

Advertisement




Oct
28
Today In Oncology
TIL Therapy Plus Pembrolizumab for Advanced Melanoma
Machine Learning Models Outperform Traditional Approaches to Multicancer Risk Prediction
Sacituzumab Tirumotecan Extends PFS OS in Advanced Recurrent Endometrial Cancer
Expert Histopathology and Molecular Testing Improve Diagnosis of Ambiguous Cutaneous Melanocytic Tumors
Radiation Added to Systemic Therapy Improves PFS But Not OS for Oligometastatic NSCLC
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo